Neonates positive for immunoreactive trypsinogen assay (IRT) and negative for sweat test have formerly been found to carry the major cystic fibrosis (CF) mutation, AF508, much more frequently than the general population. Among the 716 IRT positive newborns detected by a three tier (IRT, mutation analysis plus meconium lactase assay, sweat test) CF screening programme in north eastern Italy during the period
Neonates positive for immunoreactive trypsinogen assay (IRT) and negative for sweat test have formerly been found to carry the major cystic fibrosis (CF) mutation, AF508, much more frequently than the general population. Among the 716 IRT positive newborns detected by a three tier (IRT, mutation analysis plus meconium lactase assay, sweat test) CF screening programme in north eastern Italy during the period January 1993 to March 1996, we found 45 carriers, a number significantly higher than the expected 17 (p<0.001). We speculated that some of these heterozygotes could actually be affected by a very mild form of CF, and carry on the other chromosome an undetected CFTR mutation or a DNA variant, such as the 5-thymidine allele in intron 8 ofthe CFTR gene (IVS8-5T). This hypothesis was tested in four samples: group A (the 45 carriers mentioned above), group B (51 non-carrier, IRT positive neonates), group C (50 IRT negative neonates), and group D (90 CF adult female carriers). Chromosomes with IVS8-5T were seven (7.78%) in group A, seven (6.86%) in group B, five (5%) in group C, and four in group D (2.22%). The ST prevalence in group A was significantly higher (p<0.05) compared to group D; similarly, a higher (p<0.05) ST frequency in group A compared to group C was detected by considering the chromosomes free from CFTR mutations. This study is consistent with previous papers in finding among neonates with high trypsin levels a CF carrier frequency significantly higher than that expected. It is also suggested that in at least some babies raised trypsin levels at birth could be a phenotypic expression of compound heterozygosity for a major CF mutation plus IVS8-5T. [16] [17] [18] The frequency of the 5T allele gradually decreased from group A to group D, with a significant difference between A and D (p=0.0459). In the seven babies who carried both IVS8-5T and a CF mutation, the latter was always AF508; in the four adults the mutations were AF508 (twice), N1303K, and Rl 162X. The explanation for such a peculiar phenomenon is a matter for conjecture. One possibility could be that neonatal IRT positivity is capable of indirectly detecting some heterozygotes who show mild biological abnormalities as early as the first days of life. However, carriers have always been considered to be clinically and biologically asymptomatic, and it is difficult to explain why some of them show this feature while others do not. Alternatively, either the carrier frequency in the general population could be more than the calculated one, or the relative frequency of the tested mutations could be higher. Both options are unlikely, the former because such a huge number of carriers would be consistent with an incidence of CF much greater than that currently observed, the latter because we have previously shown the distribution of CF mutations in our population by characterising more than 90% of the mutated alleles from a cohort of 225 CF chromosomes.
Finally, one could postulate that at least some of these newborns carry an undetectable mild mutation or a DNA variant on the other chromosome, associated with normal sweat chloride values, but capable of raising trypsin levels.
A polymorphic repeat which could play this role is the 5-thymidine allele in intron 8 . The proportion of the exon 9 transcript is inversely related to the length of the poly-thymidine tract in the sequence of the acceptor splice site of intron 8, the 5T allele causing a high proportion of an abnormal, alternatively spliced CFTR mRNA.24 Subjects with one CF mutation on one chromosome and the 5T allele on the other have little normal CFTR, and their phenotypes are quite diverse, including mild CF, disseminated bronchiectasis, CBAVD, and the absence of fertility problems.425 2 We speculate that neonatal hypertrypsinaemia could also be included in this wide clinical spectrum. In fact, the prevalence of the 5T allele was only slightly higher in group A compared to B, and in B compared to C.
The differences in the IVS8-5T frequencies would become much higher (group A v C, p<0.05) if we considered two chromosomes per subject in groups B (7/102) To follow this convention and at the same time overcome the difficulties connected with contrasting genetically heterogeneous populations like A, B, and C, we chose to compare two samples of carriers, the IRT positive and CF heterozygous babies in group A and a control population of female CF carriers (group D). The significantly higher (p<0.05) prevalence of the IVS8-5T variant which we found in the former substantiates the hypothesis that some of these newborns are actually affected by a very mild form of CF, thus explaining the high IRT levels. Similarly, it could be speculated that other CFTR variants or mild mutations were actually responsible for the hypertrypsinaemia in the remaining neonates in group A' and, when affecting both chromosomes, in the ones in group B. A thorough study of the CFTR gene in these subjects should clarify the issue.
In conclusion, the incidence of CF carriers in infants with a raised IRT is higher than the one expected in the general population. In at least some babies raised trypsin levels at birth could be a phenotypic expression of compound heterozygosity for a major CF mutation plus the 5T polymorphism. Considering the wide range of manifestations connected with this genotype, which can range from completely healthy to CBAVD or even mild CF, it is extremely difficult to predict the clinical outcome of these newborns, and to provide satisfactory genetic counselling for the family. Close clinical follow up should help in clarifying the extent of the disease in these subjects, with special regard to the three males, who could possibly turn out to be affected by CBAVD.
Newborn CF carriers with hypertrypsinaemia should perhaps deserve a closer look before being dismissed as "unaffected".
